Cardiotoxicity with Rituximab, Cyclophosphamide, Non-pegylated Liposomal Doxorubicin, Vincristine and Prednisolone compared to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone in Frontline Treatment of Patients with Diffuse...
Overview
Authors
Affiliations
Background: Chemoimmunotherapy containing rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is the standard treatment for diffuse large B-cell lymphoma (DLBCL). Doxorubicin may induce early and late cardiotoxicity. Non-pegylated liposomal (NPL) doxorubicin may reduce cardiotoxicity.
Patients And Methods: Patients with untreated CD20+ DLBCL were randomised to conventional R-CHOP chemoimmunotherapy or rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone (R-COMP) with doxorubicin substituted by NPL-doxorubicin. Left ventricular ejection fraction (LVEF) and N-terminal pro B-type natriuretic peptide (NT-proBNP) levels were measured before each treatment cycle and after the end of treatment.
Results: The mean LVEF of 178 and 158 measurements in the R-COMP and R-CHOP arms was 63.31% and 62.25%, respectively (P = 0.167). During treatment the LVEF measurements were below 50% in 10/218 (4.6%) in the R-COMP arm and 31/196 (15.8%) in the R-CHOP arm (P<0.001). Thirty-six of 40 (90%) patients in the R-COMP arm, but only 24/36 (66.7%) in the R-CHOP arm had all NT-proBNP levels below 400 pg/ml during and at the end of treatment (P = 0.013). There were more serious adverse events in the R-CHOP arm (26 versus 40, P = 0.029). Infections were more common (15 versus 28) in the R-CHOP arm.
Interpretation: In patients with normal cardiac function, six cycles of R-CHOP resulted in a low rate of early cardiotoxicity. NPL-doxorubicin did not reduce cardiotoxicity, although cardiac safety signals were elevated in R-CHOP compared to R-COMP.
Funding: Cephalon provided the Arbeitsgemeinschaft Medikamentöse Tumortherapie with NPL-doxorubicin and an unrestricted grant, but was not involved in the study protocol, data acquisition, data analysis or the writing of the paper.
Doxorubicin or Epirubicin Versus Liposomal Doxorubicin Therapy-Differences in Cardiotoxicity.
Buchalska B, Kaminska K, Kowara M, Sobiborowicz-Sadowska A, Cudnoch-Jedrzejewska A Cardiovasc Toxicol. 2025; 25(2):248-268.
PMID: 39810066 DOI: 10.1007/s12012-024-09952-4.
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N JACC CardioOncol. 2025; 6(6):815-834.
PMID: 39801647 PMC: 11711816. DOI: 10.1016/j.jaccao.2024.06.005.
Upshaw J, Nelson J, Sweigart B, Rodday A, Kumar A, Konstam M JACC CardioOncol. 2024; 6(2):200-213.
PMID: 38774008 PMC: 11103040. DOI: 10.1016/j.jaccao.2024.02.003.
Cao L, Wang X, Yan Y, Ning Z, Ma L, Li Y Medicine (Baltimore). 2023; 102(51):e36705.
PMID: 38134062 PMC: 10735158. DOI: 10.1097/MD.0000000000036705.
Mo Z, Deng Y, Bao Y, Liu J, Jiang Y Cancer Med. 2023; 12(24):21709-21724.
PMID: 38054208 PMC: 10757145. DOI: 10.1002/cam4.6730.